It is clinically classified by the presence or absence of hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) and human epidermal growth factor receptor type 2 (HER2), which define the cancer subtype: Hormone-positive, HER2 positive, or triple-negative (TNBC). Here, PGR is linked to cancer.